Last reviewed · How we verify
CSTI-500
At a glance
| Generic name | CSTI-500 |
|---|---|
| Also known as | AMR-001181 |
| Sponsor | ConSynance Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of CSTI-500 in Patients With Prader-Willi Syndrome (PHASE2)
- A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSTI-500 CI brief — competitive landscape report
- CSTI-500 updates RSS · CI watch RSS
- ConSynance Therapeutics portfolio CI